von Willebrand factor antigen: a novel on-treatment predictor of response to antiviral therapy in chronic hepatitis C genotypes 1 and 4

Levels of von Willebrand factor antigen (vWF-Ag) increase during combination antiviral therapy of chronic hepatitis C (CHC). The present study investigates the association between these changes in vWF-Ag levels and response to treatment. Changes in levels of vWF-Ag on antiviral combination treatment...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Antiviral therapy 2010-01, Vol.15 (6), p.831-839
Hauptverfasser:	PRAMHAS, Sibylle, HOMONCIK, Monika, FERENCI, Peter, FERLITSCH, Arnulf, SCHERZER, Thomas, GANGL, Alfred, PECK-RADOSAVLJEVIC, Markus
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Antiviral Agents - therapeutic use Biological and medical sciences Drug Therapy, Combination Female Genotype Hepatitis C virus Hepatitis C, Chronic - drug therapy Human viral diseases Humans Infectious diseases Male Medical sciences Middle Aged Pharmacology. Drug treatments Predictive Value of Tests Prospective Studies Recurrence Ribavirin - administration & dosage Ribavirin - therapeutic use Viral diseases Viral hepatitis von Willebrand Factor - immunology von Willebrand Factor - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Levels of von Willebrand factor antigen (vWF-Ag) increase during combination antiviral therapy of chronic hepatitis C (CHC). The present study investigates the association between these changes in vWF-Ag levels and response to treatment. Changes in levels of vWF-Ag on antiviral combination treatment in 184 patients with CHC genotype 1 or 4 infections were measured prospectively and effect on response was studied. High on-treatment levels of vWF-Ag were associated with relapse (P
ISSN:	1359-6535 2040-2058
DOI:	10.3851/IMP1654